Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales
AE El‐Kenawi, AB El‐Remessy - British journal of …, 2013 - Wiley Online Library
Angiogenesis, a process of new blood vessel formation, is a prerequisite for tumour growth
to supply the proliferating tumour with oxygen and nutrients. The angiogenic process may …
to supply the proliferating tumour with oxygen and nutrients. The angiogenic process may …
Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4 (3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma
A series of new VEGFR-2 inhibitors were designed, synthesized and evaluated for their anti-
proliferative activities against hepatocellular carcinoma (HepG-2 cell line). Compound 29 b …
proliferative activities against hepatocellular carcinoma (HepG-2 cell line). Compound 29 b …
Targeted therapy for hepatocellular carcinoma: old and new opportunities
C Laface, P Fedele, FM Maselli, F Ambrogio, C Foti… - Cancers, 2022 - mdpi.com
Simple Summary Hepatocellular carcinoma (HCC) is the most frequent primitive cancer of
the liver, accounting for 90% of all recorded cases. HCC is the third most common cause of …
the liver, accounting for 90% of all recorded cases. HCC is the third most common cause of …
Anti-angiogenesis triggers exosomes release from endothelial cells to promote tumor vasculogenesis
Y Zeng, X Yao, X Liu, X He, L Li, X Liu… - Journal of …, 2019 - Taylor & Francis
Although anti-angiogenic therapies (AATs) have some effects against multiple malignancies,
they are limited by subsequent tumor vasculogenesis and progression. To investigate the …
they are limited by subsequent tumor vasculogenesis and progression. To investigate the …
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
P Ghatalia, Y Je, MD Kaymakcalan… - British Journal of …, 2015 - nature.com
Background: Multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine
kinase inhibitors (TKIs) are known to cause cardiac toxicity, but the relative risk (RR) of QTc …
kinase inhibitors (TKIs) are known to cause cardiac toxicity, but the relative risk (RR) of QTc …
PLAGL2‐EGFR‐HIF‐1/2α signaling loop promotes HCC progression and erlotinib insensitivity
W Hu, S Zheng, H Guo, B Dai, J Ni, Y Shi, H Bian… - …, 2021 - Wiley Online Library
Background and Aims Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐
related deaths worldwide, hence a major public health threat. Pleomorphic adenoma gene …
related deaths worldwide, hence a major public health threat. Pleomorphic adenoma gene …
Advances of targeted therapy for hepatocellular carcinoma
M Niu, M Yi, N Li, K Wu, K Wu - Frontiers in Oncology, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is one of the common and fatal malignancies, which is a
significant global health problem. The clinical applicability of traditional surgery and other …
significant global health problem. The clinical applicability of traditional surgery and other …
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system
JM Huelse, DM Fridlyand, S Earp, D DeRyckere… - Pharmacology & …, 2020 - Elsevier
The receptor tyrosine kinase MERTK is aberrantly expressed in numerous human
malignancies, and is a novel target in cancer therapeutics. Physiologic roles of MERTK …
malignancies, and is a novel target in cancer therapeutics. Physiologic roles of MERTK …
Systemic therapy for hepatocellular carcinoma: current updates and outlook
Y Fan, H Xue, H Zheng - Journal of Hepatocellular Carcinoma, 2022 - Taylor & Francis
Hepatocellular carcinoma (HCC) has emerged the culprit of cancer-related mortality
worldwide with its dismal prognosis climbing. In recent years, ground-breaking progress has …
worldwide with its dismal prognosis climbing. In recent years, ground-breaking progress has …